奥氮平预防含顺铂方案化疗所致迟发性呕吐的临床观察  

作　　者：王伟英[1] 李海金[1] 尚官敏[1] 葛丽娜[1] 董良[1] 

机构地区：[1]中国医科大学绍兴医院肿瘤内科,312030

出　　处：《浙江临床医学》2017年第4期675-676,共2页Zhejiang Clinical Medical Journal

摘　　要：目的观察奥氮平治疗舍顺铂方案化疗所致迟发性呕吐的疗效。方法对应用舍顺铂方案化疗的86例肺癌患者随机分为治疗组和对照组，每组各43例。对照组给予常规药物治疗呕吐，治疗组是在常规药物的基础上于顺铂应用前一天晚上开始加用奥氮平片10mg口服，每晚一次，连用7d，观察两组迟发性恶心呕吐的发生情况。结果治疗组和对照组急性恶心、呕吐的发生率分别是16．28％（7／43）和25．58％（11／43），两组比较差异无统计学意义（P〉0．05）；而治疗组和对照组迟发性恶心、呕吐发生率分别是18．60％（8／43）和67．44％（29／43），两组比较差异有统计学意义（P〈0．05），且发生级别治疗组也明显低于对照组。结论奥氮平对合顺铂方案化疗所致迟发性恶心呕吐疗效确切．其他不良反应不明显。Objective To observe the efficacy and adverse reactions of olanzapine combined with tropisetron and dexamethasone in preventing the incidence of delayed nausea and vomiting induced by cisplatin. Methods A total of 86 patients with lung cancer were randomly divided into two groups： the olanzapine group was given olanzapine 10 mg for 7 days from the day before chemotherapy. Both the olanzapine group and the control group were given tropisetron and dexamethasone during chemotherapy, The efficacy and adverse reactions of the two groups were recorded. Results The treatment group and the control group of acute nausea and vomiting rate were 16.28% （ 7/43 ） and 25,58% （ 11/43 ） , the two groups had no statistically significant difference （ P〉0.05 ） ; while the treatment group and the control group delayed nausea and vomiting incidence rates were 18.60% （ 8/43 ） and 67.44% （ 29/43 ） , the difference was statistically significant （ P〈0.05 ） , and the occurrence level of the treatment group was significantly lower than the control group. Conclusion Olanzapine can improve cisplafin-induced nausea and vomiting with well-tolerated adverse reactions.

关 键 词：奥氮平 顺铂 化疗 迟发性 呕吐 

分 类 号：R730.53[医药卫生—肿瘤]